Literature DB >> 35221865

Augustine Blood Group System and Equilibrative Nucleoside Transporter 1.

Geoff Daniels1.   

Abstract

Augustine (AUG) is a blood group system comprising four antigens: AUG1, AUG2 (Ata), and AUG4 are of very high frequency; AUG3 is of very low frequency. These antigens are located on ENT1, an equilibrative nucleoside transporter encoded by SLC19A1. AUG antibodies are of clinical relevance in blood transfusion and pregnancy: anti-AUG2 have caused haemolytic transfusion reactions; the only anti-AUG3 was associated with severe haemolytic disease of the fetus and newborn. ENT1 is present in almost all human tissues. It facilitates the transfer of purine and pyrimidine nucleosides and is responsible for the majority of adenosine transport across plasma membranes. Adenosine transport appears to be an important factor in the regulation of bone metabolism. The AUGnull phenotype (AUG:-1,-2,-3,-4) has been found in three siblings, who are homozygous for an inactivating splice-site mutation in SLC29A1. Although ENT1 is very likely to be absent from all cells in these three individuals, they were apparently healthy with normal lifestyles. However, they suffered frequent attacks of pseudogout, a form of arthritis, in various joints with multiple calcifications around their hand joints. Ectopic calcification in the hips, pubic symphysis, and lumbar discs was present in the propositus. The three AUGnull individuals had misshapen red cells with deregulated protein phosphorylation, but no anaemia or shortening of red cell lifespan. Defective in vitro erythropoiesis in the absence of ENT1 was confirmed by shRNA-mediated knockdown of ENT1 during in vitro erythropoiesis of CD34+ progenitor cells from individuals with normal ENT1. Nucleoside transporters, such as ENT1, are vital in the uptake of synthetic nucleoside analogue drugs, used in cancer and viral chemotherapy. It is feasible that the efficacy of these drugs would be compromised in patients with the extremely rare AUGnull phenotype.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Arthritis; Augustine blood group system; ENT1; Erythropoiesis; SLC29A1

Year:  2021        PMID: 35221865      PMCID: PMC8832251          DOI: 10.1159/000520596

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  40 in total

1.  A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies.

Authors:  Patricia A Arndt; George Garratty
Journal:  Transfusion       Date:  2004-09       Impact factor: 3.157

2.  Low SLC29A1 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Ping-Ting Gao; Jian-Wen Cheng; Zi-Jun Gong; Bo Hu; Yun-Fan Sun; Ya Cao; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

3.  A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn.

Authors:  Glenda M Millard; Eunike C McGowan; Brett Wilson; Jacqui R Martin; Michaela Spooner; Scott Morris; Ray Farley; Simon James; Yew-Wah Liew; Elizna M Schoeman; Melinda M Dean; Robert L Flower; Catherine A Hyland; Tanya Powley; David Roxby
Journal:  Transfusion       Date:  2018-03-05       Impact factor: 3.157

4.  Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.

Authors:  Geoff Daniels; Bryan A Ballif; Virginie Helias; Carole Saison; Shane Grimsley; Lucienne Mannessier; Hein Hustinx; Edmond Lee; Jean-Pierre Cartron; Thierry Peyrard; Lionel Arnaud
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

5.  Ata (August) and El (Eldr) are synonymous.

Authors:  A Brown; P Harris; G L Daniels; S Frank; B P Moore; R Berger
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

6.  Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1.

Authors:  Douglas H Osato; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Joanne Wang; Thomas E Ferrin; Ira Herskowitz; Kathleen M Giacomini
Journal:  Pharmacogenetics       Date:  2003-05

7.  Clinical significance of anti-At(a).

Authors:  G Ramsey; L A Sherman; A M Zimmer; W G Spies; L Sharma; P Arndt; G Garratty
Journal:  Vox Sang       Date:  1995       Impact factor: 2.144

8.  The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.

Authors:  Christopher J Endres; Aaron M Moss; Ban Ke; Rajgopal Govindarajan; Doo-Sup Choi; Robert O Messing; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-01-22       Impact factor: 4.030

9.  Genotyping confirms inheritance of the rare At(a-) type in a case of haemolytic disease of the newborn.

Authors:  Rhiannon McBean; Yew-Wah Liew; Brett Wilson; Pawinee Kupatawintu; Morakot Emthip; Catherine Hyland; Robert Flower
Journal:  J Pathol Clin Res       Date:  2015-12-11

10.  GATA factor-regulated solute carrier ensemble reveals a nucleoside transporter-dependent differentiation mechanism.

Authors:  Nicole M Zwifelhofer; Xiaoli Cai; Ruiqi Liao; Bin Mao; Daniel J Conn; Charu Mehta; Sunduz Keles; Yang Xia; Emery H Bresnick
Journal:  PLoS Genet       Date:  2020-12-28       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.